How once-nightly sodium oxybate is processed in the body in healthy volunteers: a plain language summary.

IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Richard Bogan, Michael J Thorpy, Sarah Berkowitz, Jennifer Gudeman
{"title":"How once-nightly sodium oxybate is processed in the body in healthy volunteers: a plain language summary.","authors":"Richard Bogan, Michael J Thorpy, Sarah Berkowitz, Jennifer Gudeman","doi":"10.57264/cer-2024-0243","DOIUrl":null,"url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a plain language summary of an article originally published in the journal Sleep Medicine. Narcolepsy is a sleep condition in which people have periods of extreme sleepiness during the day. People with narcolepsy may also have symptoms of muscle weakness (cataplexy); seeing, hearing, smelling, tasting, or feeling something that seems real but isn't actually there before falling asleep or while waking up (hallucinations); an inability to move before falling asleep or while waking up (sleep paralysis); and poor sleep at night. Sodium oxybate (SXB for short) has been used to treat narcolepsy for over 20 years. For more than 20 years, the only available form of SXB needed to be taken twice each night. Twice-nightly SXB (TN-SXB) requires people to take the first dose at bedtime. Most people fall asleep within 5 to 15 minutes after the first dose. Patients then need to wake up and take the second dose of TN-SXB 2.5 to 4 hours later, which is when most of the medicine has left the body. The United States Food and Drug Administration (also called FDA) approved a once-nightly form of SXB called LUMRYZ<sup>™</sup> (sodium oxybate for extended-release oral suspension; ON-SXB for short) in May 2023. ON-SXB treats excessive daytime sleepiness and muscle weakness, also known as cataplexy. People with narcolepsy who take ON-SXB only need to take 1 dose at bedtime. This summary describes a study that looked at how ON-SXB enters, travels through, and exits the body of healthy volunteers (people without narcolepsy). The study measured the amount of SXB in the blood after taking SXB in 2 different ways: as a once-nightly version and as a twice-nightly version. Looking at the amount of ON-SXB and TN-SXB in the blood at different time points helps researchers see if people who take the 2 medicines, with different dosing, have the same amount of drug in the body overnight.</p><p><strong>What were the results?: </strong>Overall, the study found that healthy volunteers had the same amount of SXB in their bodies after taking ON-SXB as they did after taking TN-SXB. When they took the same amounts of ON-SXB and TN-SXB, the SXB stayed in their bodies for similar amounts of time. The highest amount and the total amount of SXB in the participants' blood were similar with ON-SXB and TN-SXB. The amount of SXB in the participants' blood 8 hours after taking the medicine was significantly lower with ON-SXB than with TN-SXB. This means that people taking ON-SXB will have less medication in their blood when they wake up the next morning and may be less groggy.</p><p><strong>What do the results mean?: </strong>The results mean that if people with narcolepsy take the same dose amount of ON-SXB or TN-SXB, their bodies will receive the same amount of SXB in their blood. ON-SXB provides an option for people with narcolepsy to take their medicine once at bedtime without the need for a middle-of-the-night dose, which can improve quality of life.</p>","PeriodicalId":15539,"journal":{"name":"Journal of comparative effectiveness research","volume":" ","pages":"e240243"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007474/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of comparative effectiveness research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.57264/cer-2024-0243","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

What is this summary about?: This is a plain language summary of an article originally published in the journal Sleep Medicine. Narcolepsy is a sleep condition in which people have periods of extreme sleepiness during the day. People with narcolepsy may also have symptoms of muscle weakness (cataplexy); seeing, hearing, smelling, tasting, or feeling something that seems real but isn't actually there before falling asleep or while waking up (hallucinations); an inability to move before falling asleep or while waking up (sleep paralysis); and poor sleep at night. Sodium oxybate (SXB for short) has been used to treat narcolepsy for over 20 years. For more than 20 years, the only available form of SXB needed to be taken twice each night. Twice-nightly SXB (TN-SXB) requires people to take the first dose at bedtime. Most people fall asleep within 5 to 15 minutes after the first dose. Patients then need to wake up and take the second dose of TN-SXB 2.5 to 4 hours later, which is when most of the medicine has left the body. The United States Food and Drug Administration (also called FDA) approved a once-nightly form of SXB called LUMRYZ (sodium oxybate for extended-release oral suspension; ON-SXB for short) in May 2023. ON-SXB treats excessive daytime sleepiness and muscle weakness, also known as cataplexy. People with narcolepsy who take ON-SXB only need to take 1 dose at bedtime. This summary describes a study that looked at how ON-SXB enters, travels through, and exits the body of healthy volunteers (people without narcolepsy). The study measured the amount of SXB in the blood after taking SXB in 2 different ways: as a once-nightly version and as a twice-nightly version. Looking at the amount of ON-SXB and TN-SXB in the blood at different time points helps researchers see if people who take the 2 medicines, with different dosing, have the same amount of drug in the body overnight.

What were the results?: Overall, the study found that healthy volunteers had the same amount of SXB in their bodies after taking ON-SXB as they did after taking TN-SXB. When they took the same amounts of ON-SXB and TN-SXB, the SXB stayed in their bodies for similar amounts of time. The highest amount and the total amount of SXB in the participants' blood were similar with ON-SXB and TN-SXB. The amount of SXB in the participants' blood 8 hours after taking the medicine was significantly lower with ON-SXB than with TN-SXB. This means that people taking ON-SXB will have less medication in their blood when they wake up the next morning and may be less groggy.

What do the results mean?: The results mean that if people with narcolepsy take the same dose amount of ON-SXB or TN-SXB, their bodies will receive the same amount of SXB in their blood. ON-SXB provides an option for people with narcolepsy to take their medicine once at bedtime without the need for a middle-of-the-night dose, which can improve quality of life.

健康志愿者每晚一次的氧化钠是如何在体内加工的:一个简单的语言总结。
这个总结是关于什么的?这是最初发表在《睡眠医学》杂志上的一篇文章的简明扼要的总结。嗜睡症是一种睡眠状态,患者在白天会有一段时间极度困倦。嗜睡症患者也可能有肌肉无力的症状(猝倒);在入睡前或醒来时看到、听到、闻到、品尝或感觉到看似真实但实际上并不存在的东西(幻觉);入睡前或醒来时不能移动(睡眠麻痹);晚上睡不好觉。氧酸钠(简称SXB)用于治疗嗜睡症已有20多年的历史。20多年来,唯一可用的SXB需要每晚服用两次。每晚两次的SXB (TN-SXB)要求人们在睡前服用第一剂。大多数人在第一次服药后5到15分钟就睡着了。然后,患者需要在2.5至4小时后醒来并服用第二剂TN-SXB,此时大部分药物已经离开身体。美国食品和药物管理局(FDA)批准了一种每晚一次的SXB,名为LUMRYZ™(氧酸钠缓释口服混凝剂;ON-SXB(简称ON-SXB)将于2023年5月上市。ON-SXB治疗白天过度嗜睡和肌肉无力,也被称为猝倒。患有嗜睡症的人服用ON-SXB只需在睡前服用一剂。这篇摘要描述了一项研究,该研究观察了ON-SXB如何进入、穿过和离开健康志愿者(没有嗜睡症的人)的身体。该研究以两种不同的方式测量了服用SXB后血液中SXB的含量:每晚服用一次和每晚服用两次。观察不同时间点血液中ON-SXB和TN-SXB的含量有助于研究人员了解服用不同剂量的两种药物的人在一夜之间体内的药物含量是否相同。结果如何?总体而言,研究发现,健康志愿者在服用ON-SXB后体内的SXB含量与服用TN-SXB后相同。当他们服用相同量的ON-SXB和TN-SXB时,SXB在他们体内停留的时间相似。受试者血液中SXB的最高含量和总量与ON-SXB和TN-SXB相似。服药8小时后,ON-SXB组血液中SXB的含量明显低于TN-SXB组。这意味着服用ON-SXB的人在第二天早上醒来时血液中的药物含量会减少,并且可能不会那么昏昏沉沉。这些结果意味着什么?这意味着,如果嗜睡症患者服用相同剂量的ON-SXB或TN-SXB,他们的身体会从血液中吸收相同数量的SXB。ON-SXB为嗜睡症患者提供了一种选择,他们可以在睡前服用一次药物,而不需要在半夜服用,这可以提高生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of comparative effectiveness research
Journal of comparative effectiveness research HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.50
自引率
9.50%
发文量
121
期刊介绍: Journal of Comparative Effectiveness Research provides a rapid-publication platform for debate, and for the presentation of new findings and research methodologies. Through rigorous evaluation and comprehensive coverage, the Journal of Comparative Effectiveness Research provides stakeholders (including patients, clinicians, healthcare purchasers, and health policy makers) with the key data and opinions to make informed and specific decisions on clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信